Literature DB >> 35084934

Disease Modification in Myelofibrosis: An Elusive Goal?

Pankit Vachhani1, Srdan Verstovsek2, Prithviraj Bose2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35084934      PMCID： PMC8987221          DOI： 10.1200/JCO.21.02246

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  67 in total

1.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

Review 2.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

3.  Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Authors:  Francesco Passamonti; Margherita Maffioli; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Tiziano Barbui; Domenica Caramazza; Lisa Pieri; Elisa Rumi; Heinz Gisslinger; Laurent Knoops; Jean Jaques Kiladjian; Barbara Mora; Norbert Hollaender; Cristiana Pascutto; Claire Harrison; Mario Cazzola
Journal:  Blood       Date:  2014-01-17       Impact factor: 22.113

4.  Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Ruben Mesa; Catriona Jamieson; Ravi Bhatia; Michael W Deininger; Aaron T Gerds; Ivana Gojo; Jason Gotlib; Krishna Gundabolu; Gabriela Hobbs; Rebecca B Klisovic; Patricia Kropf; Sanjay R Mohan; Stephen Oh; Eric Padron; Nikolai Podoltsev; Daniel A Pollyea; Raajit Rampal; Lindsay A M Rein; Bart Scott; David S Snyder; Brady L Stein; Srdan Verstovsek; Martha Wadleigh; Eunice S Wang; Mary Anne Bergman; Kristina M Gregory; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-12       Impact factor: 11.908

5.  MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.

Authors:  Srdan Verstovsek; Chih-Cheng Chen; Miklós Egyed; Martin Ellis; Laura Fox; Yeow T Goh; Vikas Gupta; Claire Harrison; Jean-Jacques Kiladjian; Mihaela C Lazaroiu; Adam Mead; Donal McLornan; Mary F McMullin; Stephen T Oh; Andrew Perkins; Uwe Platzbecker; Christof Scheid; Alessandro Vannucchi; Sung-Soo Yoon; Mark M Kowalski; Ruben A Mesa
Journal:  Future Oncol       Date:  2021-01-11       Impact factor: 3.404

6.  Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

Authors:  Keyur P Patel; Kate J Newberry; Rajyalakshmi Luthra; Elias Jabbour; Sherry Pierce; Jorge Cortes; Rajesh Singh; Meenakshi Mehrotra; Mark J Routbort; Madan Luthra; Taghi Manshouri; Fabio P Santos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

7.  Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.

Authors:  John Mascarenhas; Maneesha Mehra; Jianming He; Ravi Potluri; Christina Loefgren
Journal:  J Med Econ       Date:  2020-03-31       Impact factor: 2.448

8.  Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

Authors:  Kate J Newberry; Keyur Patel; Lucia Masarova; Rajyalakshmi Luthra; Taghi Manshouri; Elias Jabbour; Prithviraj Bose; Naval Daver; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113

Review 9.  Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.

Authors:  Andrew T Kuykendall; Nathan P Horvat; Garima Pandey; Rami Komrokji; Gary W Reuther
Journal:  Cancers (Basel)       Date:  2020-08-14       Impact factor: 6.639

10.  A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.

Authors:  A Pardanani; A Tefferi; C Jamieson; N Y Gabrail; C Lebedinsky; G Gao; F Liu; C Xu; H Cao; M Talpaz
Journal:  Blood Cancer J       Date:  2015-08-07       Impact factor: 11.037
View more
  1 in total

Review 1.  Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis.

Authors:  Harinder Gill
Journal:  Cells       Date:  2022-07-03       Impact factor: 7.666
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.